BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2025.
World J Gastrointest Endosc. Nov 16, 2025; 17(11): 110436
Published online Nov 16, 2025. doi: 10.4253/wjge.v17.i11.110436
Table 3 Clinical and endoscopic outcomes (n = 79)

n (%)
Mean follow-up, months, mean ± SD26.3 ± 21.8
Early follow-up (3-6 months)
Residual adenoma4 (5.1)
Management of residual adenoma
    EMR2 (2.5)
    ESD2 (2.5)
Late follow up (> 6 months)
Mean time to recurrence ± SD, months18.0 ± 15
Recurrent adenoma
    Local9 (11.4)
    Metachronous1 (1.3)
Management of recurrent adenoma
    EMR6 (7.6)
    ESD4 (5.1)
Pathology of recurrent adenoma
    LGD7 (8.9)
    HGD2 (2.5)
Intramucosal adenocarcinoma (T1a)1 (1.3)


Write to the Help Desk